Loading...
Current evidence for immune checkpoint inhibition in advanced hepatocellular carcinoma
Foy, Victoria McNamara, Mairead G Lamarca, Angela Edeline, J.
Foy, Victoria
McNamara, Mairead G
Lamarca, Angela
Edeline, J.
Citations
Altmetric:
Abstract
The treatment of advanced unresectable HCC (aHCC) remains a clinical challenge, with limited therapeutic options and poor prognosis. The results of IMbrave150 and HIMALAYA have changed the treatment paradigm for HCC and established immune checkpoint inhibition (ICI), either combined with anti-angiogenic therapy or dual ICI, as preferred first-line therapy for eligible patients with aHCC. Numerous other combination regimens involving ICI are under investigation with the aim of improving the tumour response and survival of patients with all stages of HCC. This review will explore the current evidence for ICI in patients with advanced HCC and discuss future directions, including the unmet clinical need for predictive biomarkers to facilitate patient selection, the effects of cirrhosis aetiology on response to ICI, and the safety of its use in patients with impaired liver function.
Description
Date
2023
Publisher
Collections
Files
Keywords
Type
Article
Citation
Foy V, McNamara MG, Valle JW, Lamarca A, Edeline J, Hubner RA. Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma. Current oncology (Toronto, Ont). 2023 Sep 21;30(9):8665-85. PubMed PMID: 37754543. Pubmed Central PMCID: PMC10529518. Epub 2023/09/27. eng.